| lamivudine HBV / Generic mfg. |
ChiCTR-OCH-12002141: Entecavir monotherapy versus de novo combination of lamivudine and adefovir for the treatment of naive HBeAg-positive chronic hepatitis B patients with High HBV viral load （the Climber study) |
|
|
| Completed | 4 | 280 | | Lamivudine 100mg po qd, Adefovir Dipivoxil 10mg po qd, for 96 weeks ;Entecvir 0.5mg po qd, for 96 weeks | Departmen of infectious disease, Tongji Hospital, Tongji medical college, Huazhong university of science and technology; Departmen of infectious disease, Tongji hospital, Tongji medical college, Huazhong university of science and technology, Sino-American Shanghai Squibb Pharmaceuticals Ltd. | chronic hepatitis B | | | | |
ChiCTR-TRC-11001258: Efficacy of lamivudine and adefovir de-novo combination therapy or optimal therapy at week 48 in chronic hepatitis B patients |
|
|
| Completed | 4 | 174 | | Adefovir 10mg/d,p.o.qd for 104 weeks or combination with Lamivudine 10mg/d,p.o.qd at 48 weeks.Total treatment time:104 weeks ;Lamivudine(LAM) 100mg/d,p.o.qd for 104 weeks or combination with Adefovir(ADV) 10mg/d,p.o.qd at 48 weeks.Total treatment time:104 weeks ;Lamivudine 100mg/d,p.o.qd +Adefovir 10mg/d,p.o.qd for 104 weeks | Department of Infectious Diseases, Guangdong General Hospital; Level of the institution：, self-financing | Chronic hepatitis B | | | | |
ChiCTR-ONRC-11001495: Lamivudine plus adefovir or telbivudine plus adefovir for chronic hepatitis B patients with suboptimal response to adefovir: a prospective controlled study |
|
|
| Completed | 4 | 80 | | Telbivudine 600 mg/day , Adefovir 10 mg/day ;Lamivudine 100 mg/day , Adefovir 10 mg/day | Center of Infctious Diseases, West China Hospital of Sichuan University; Center of Infctious Diseases, West China Hospital of Sichuan University, self-funding | Chronic hepatitis B | | | | |
ChiCTR-ONRC-12001924: Efficacy and safety of defovir dipivoxil in children with interferon therapy unresponsive and lamivudine- resistance chronic hepatitis B |
|
|
| Completed | 4 | 30 | | Adefovir 0.25mg/kg/d,p.o.qd for three years.ADV dose is not to exceed 10 mg/day. | Affiliated Second Hospital, Southeast University, Nanjing; Affiliated Second Hospital, Southeast University, Nanjing, Self-finance | Chronic hepatitis B | | | | |
2011-000629-55: CLINICAL TRIAL WITH TENOFOVIR VERSUS LAMIVUDINE PLUS ADEFOVIR DIPIVOXIL IN LAMIVUDINE-RESISTANT CHRONIC HEPATITIS-B PATIENTS WITH UNDETECTABLE VIRAL LOAD ENSAYO CLÍNICO DE SIMPLIFICACIÓN CON TENOFOVIR EN PACIENTES CON HEPATITIS CRÓNICA B RESISTENTES A LAMIVUDINA Y CARGA VIRAL INDETECTABLE EN TRATAMIENTO CON LAMIVUDINA MÁS ADEFOVIR DIPIVOXIL (Estudio TENOSIMP-B) |
|
|
| Ongoing | 4 | 100 | Europe | VIREAD, ZEFFIX, HEPSERA, J05AF07, VIREAD, ZEFFIX, HEPSERA, VIREAD, ZEFFIX, HEPSERA | Manuel Rodríguez García, Gilead Sciences, Inc. | CHRONIC HEPATITIS B HEPATITIS CRÓNICA B | | | | |
ChiCTR-TRC-12002121: Preventive use of lamivudine in postgastrectomy adenocarcinoma patients carrying HBV to prevent from severe liver damage and viral activation |
|
|
| Completed | 3 | 60 | | lamivudine ;Radiotherapy combined with Chemotherapy that contains oxaliplatin | West China Hospital, Sichuan University; Level of the institution：, Hospital funding | gastric cancer and HBV | | | | |
ChiCTR2400084217: Reactivation of hepatitis B virus in HIV patients with HBcAb positive/HBsAg negative after switching to a two-drug regimen lamivudine-based treatment |
|
|
| Not yet recruiting | N/A | 212 | | None; None | Beijing Ditan Hospital; Ditan hospital, Beijing Municipal Finance Special Funds and Self-financing Funds | HIV/AIDS | | | | |
